CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugarThe EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment Share XCHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugarhttps://pharmaphorum.com/news/chmp-backs-lillys-baqsimi-as-non-injectable-for-severe-low-blood-sugar/
FDA approves AZ’s Farxiga in new heart failure prevention useThe FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in Share XFDA approves AZ’s Farxiga in new heart failure prevention usehttps://pharmaphorum.com/news/fda-approves-azs-farxiga-in-new-heart-failure-prevention-use/
Roche app allows access to latest cancer guidelinesRoche has launched an app allowing access to the latest guidelines covering the most common forms of cancer. Share XRoche app allows access to latest cancer guidelineshttps://pharmaphorum.com/news/roche-app-allows-access-to-latest-cancer-guidelines/
CHMP backs world’s first Ebola vaccine from MSD, NewLinkMerck & Co/MSD’s Ebola vaccine has been recommended for conditional approval by the EMA’s main advisory committee, teeing Share XCHMP backs world’s first Ebola vaccine from MSD, NewLinkhttps://pharmaphorum.com/news/chmp-backs-worlds-first-ebola-vaccine-from-msd-newlink/
Lawsuit-laden J&J recalls baby powder after asbestos alertJohnson & Johnson has said it is recalling around 33,000 bottles of baby powder in the US, after Share XLawsuit-laden J&J recalls baby powder after asbestos alerthttps://pharmaphorum.com/news/lawsuit-laden-jj-recalls-baby-powder-after-asbestos-alert/
Hall & Partners appoints Stacy Vaughn to senior US health roleHall & Partners Health has appointed Stacy Vaughn as managing partner of its US healthcare team, one of Share XHall & Partners appoints Stacy Vaughn to senior US health rolehttps://pharmaphorum.com/news/hall-partners-stacy-vaughn-beth-stagg/
Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535mIpsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a Share XIpsen adds Blueprint’s FOP rare disease drug to pipeline for $535mhttps://pharmaphorum.com/news/ipsen-adds-blueprints-fop-rare-disease-drug-to-pipeline-for-535m/
Is the US opioid litigation nearing an end game?Drugmakers, wholesalers and lawmakers in the US are said to be thrashing out the details of a big Share XIs the US opioid litigation nearing an end game?https://pharmaphorum.com/news/is-the-us-opioid-litigation-nearing-an-end-game/
Patient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drugUCB/Amgen’s osteoporosis drug Evenity (romosozumab) looks set for approval in Europe after regulators finally recommended it, following a Share XPatient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drughttps://pharmaphorum.com/news/ucb-overcomes-eu-no-for-osteoporosis-drug-with-patient-testimony/
